



FACSIMILE



NOTICE OF CONFIDENTIALITY

This transmission is intended only for the use of the Addressee and may contain information that is: 1. Subject to attorney/client privilege; 2. Attorney work product; or 3. Confidential. If you are not the intended recipient, you are hereby notified that any dissemination, distribution or copying of the information contained in this facsimile is strictly unauthorized and prohibited. If you have received this facsimile in error, please notify us immediately by collect telephone to the sender named below.

DATE: April 14, 2003

VIA FACSIMILE ONLY

TO: Examiner Blessing M. Fubara
FX-703-746-5013

NUMBER OF PAGES 10
FROM: James T. Jones
PFIZER INC.
PATENT DEPARTMENT
EASTERN POINT ROAD
GROTON, CT 06340
(860) 441-4903

RE: PC9674BJTJ
Serial No. 09/770,562

FACSIMILE NO.: (860) 441-5221

FACSIMILE UNIT: XEROX 745

Please see attached Supplemental Amendment Under 37 CFR 1.312

17/ Suppl E
(R312)

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to Examiner Blessing M. Fubara
at the ~~United States Patent and Trademark Office~~, fax no. 703-746-5013, on April 14, 2003

by

Patricia Botelho

PATENT PC9674BJTJ

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Beet
5-12-03

APPLICANT: William J. Curatolo, et al.

SERIAL NO.: 09/770,562

: Examiner: B. Fubara

: Art Unit: 1615

FILED: January 26, 2001

FOR: Solid Pharmaceutical Dispersions
With Enhanced Bioavailability

Assistant Commissioner For Patents
Washington, D.C. 20231

SUPPLEMENTAL AMENDMENT UNDER 37 CFR 1.312

In the above allowed application in which the Issue Fee is being paid on the
same day, please make the following amendments:

In the claims:

1. (Three Times Amended) A composition of matter comprising a
spray dried solid dispersion, which dispersion

is homogeneous;

comprises a sparingly water-soluble drug having a dose to aqueous
solubility ratio greater than 100 mL and hydroxypropylmethylcellulose acetate
succinate (HPMCAS),

provides a maximum concentration of said drug in a use environment that
is higher by a factor of at least 1.5 relative to a control composition comprising
an equivalent quantity of undispersed drug; and

E